Article Text
PostScript
Letters
Archimedes: does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
Statistics from Altmetric.com
We were surprised by some of the comments of Winckworth and Powell1 about the Caffeine for Apnea of Prematurity (CAP) trial.2 The authors concluded that the CAP trial had a ‘large preanalysis dropout rate (up to 15%)’. We correct this serious misunderstanding in table 1 which shows the number of children who had missing data for the outcome of death or disability at 18 months, …
Footnotes
-
Competing interests None.
-
Provenance and peer review Not commissioned; externally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions